CN1805747A - 4－( 4－(杂环基烷氧基 )苯基)－1－(杂环基－羰基)哌啶衍生物和相关的化合物作为组胺h3拮抗剂用于治疗神经疾病如阿尔茨海默氏病 - Google Patents

4－( 4－(杂环基烷氧基 )苯基)－1－(杂环基－羰基)哌啶衍生物和相关的化合物作为组胺h3拮抗剂用于治疗神经疾病如阿尔茨海默氏病 Download PDF

Info

Publication number
CN1805747A
CN1805747A CNA2004800161953A CN200480016195A CN1805747A CN 1805747 A CN1805747 A CN 1805747A CN A2004800161953 A CNA2004800161953 A CN A2004800161953A CN 200480016195 A CN200480016195 A CN 200480016195A CN 1805747 A CN1805747 A CN 1805747A
Authority
CN
China
Prior art keywords
phenyl
carbonyl
piperidinyl
oxy
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800161953A
Other languages
English (en)
Chinese (zh)
Inventor
马克·J·班福德
戴维·K·迪安
戴维·M·威尔逊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CN1805747A publication Critical patent/CN1805747A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2004800161953A 2003-04-10 2004-04-08 4－( 4－(杂环基烷氧基 )苯基)－1－(杂环基－羰基)哌啶衍生物和相关的化合物作为组胺h3拮抗剂用于治疗神经疾病如阿尔茨海默氏病 Pending CN1805747A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0308333.4 2003-04-10
GBGB0308333.4A GB0308333D0 (en) 2003-04-10 2003-04-10 Novel compounds

Publications (1)

Publication Number Publication Date
CN1805747A true CN1805747A (zh) 2006-07-19

Family

ID=9956580

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800161953A Pending CN1805747A (zh) 2003-04-10 2004-04-08 4－( 4－(杂环基烷氧基 )苯基)－1－(杂环基－羰基)哌啶衍生物和相关的化合物作为组胺h3拮抗剂用于治疗神经疾病如阿尔茨海默氏病

Country Status (22)

Country Link
US (1) US20060205774A1 (enExample)
EP (1) EP1610786B9 (enExample)
JP (1) JP2006522771A (enExample)
KR (1) KR20050111638A (enExample)
CN (1) CN1805747A (enExample)
AR (1) AR044006A1 (enExample)
AT (1) ATE365039T1 (enExample)
AU (1) AU2004228949B2 (enExample)
BR (1) BRPI0409110A (enExample)
CA (1) CA2521899A1 (enExample)
CO (1) CO5640135A2 (enExample)
DE (1) DE602004007119T2 (enExample)
ES (1) ES2288681T3 (enExample)
GB (1) GB0308333D0 (enExample)
IS (1) IS8118A (enExample)
MA (1) MA27726A1 (enExample)
MX (1) MXPA05010816A (enExample)
NO (1) NO20055256L (enExample)
RU (1) RU2005134006A (enExample)
TW (1) TW200503710A (enExample)
WO (1) WO2004089373A1 (enExample)
ZA (1) ZA200507795B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113453762A (zh) * 2019-03-05 2021-09-28 卫材R&D管理有限公司 五环杂环化合物

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050256118A1 (en) * 2004-05-12 2005-11-17 Altenbach Robert J Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
EP1717235A3 (en) * 2005-04-29 2007-02-28 Bioprojet Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
EP1892241B1 (en) 2005-05-30 2016-03-30 Msd K.K. Novel piperidine derivative
ES2371774T3 (es) * 2005-06-03 2012-01-10 Abbott Laboratories Derivados de ciclobutilamina.
CA2609957A1 (en) 2005-06-20 2007-01-04 Schering Corporation Carbon-linked substituted piperidines and derivatives thereof useful as histamine h3 antagonists
DE602006010870D1 (de) 2005-06-20 2010-01-14 Schering Corp Als antagonisten von histamin h3 geeignete piperidinderivate
GB0514812D0 (en) * 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
WO2007035703A1 (en) 2005-09-20 2007-03-29 Schering Corporation 1- [ [1- [ (2-amin0-6-methyl-4-pyridinyl) methyl] -4-flu0r0-4-piperidinyl,] carbonyl] -4- [2- (2-pyridinyl) -3h-imidaz0 [4 , 5-b] pyridin-3-yl] piperidine useful as histamine h3 antagonist
US7943605B2 (en) 2005-10-27 2011-05-17 Ucb Pharma S.A. Compounds comprising a lactam or a lactam derivative moiety, processes for making them, and their uses
PE20071068A1 (es) 2005-12-20 2007-12-13 Glaxo Group Ltd Acido 3-(4-{[4-(4-{[3-(3,3-dimetil-1-piperidinil)propil]oxi}fenil)-1-piperidinil]carbonil}-1-naftalenil)propanoico o propenoico, sales de los mismos, como antagonistas de los receptores h1 y h3
JP2009521448A (ja) 2005-12-21 2009-06-04 シェーリング コーポレイション ヒスタミンｈ３アンタゴニストとして有用なフェノキシピペリジンおよびそのアナログ
AU2006331850A1 (en) 2005-12-21 2007-07-05 Schering Corporation Substituted aniline derivatives useful as histamine H3 antagonists
EP2502918B1 (en) 2006-07-25 2015-03-25 Cephalon, Inc. Pyridazinone Derivatives
TW200823204A (en) * 2006-10-17 2008-06-01 Arena Pharm Inc Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
KR101108109B1 (ko) * 2007-01-22 2012-02-06 화이자 프로덕츠 인코포레이티드 치료 화합물의 토실레이트 염 및 이의 약학 조성물
AU2008279447A1 (en) 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
BRPI0914891A2 (pt) * 2008-06-20 2015-11-24 Metabolex Inc agonistas de aril gpr119 e usos dos mesmos
EP2483281B1 (en) 2009-10-01 2014-06-04 Cymabay Therapeutics, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
BR112012032248A2 (pt) 2010-06-23 2016-09-13 Metabolex Inc composições de 5-etil-2-{4-[-4(-4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina
BR112014013461A2 (pt) 2011-12-08 2017-06-13 Taisho Pharmaceutical Co Ltd derivado de fenilpirrol
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
HUP1300139A2 (en) * 2013-03-06 2014-09-29 Richter Gedeon Nyrt Phenoxypiperidine h3 antagonists
JP6426694B2 (ja) 2013-03-15 2018-11-21 グローバル ブラッド セラピューティクス インコーポレイテッド ヘモグロビンの修飾のための化合物及びその使用
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
CN106715440B (zh) 2015-04-21 2019-02-22 江苏恒瑞医药股份有限公司 咪唑并异吲哚类衍生物、其制备方法及其在医药上的应用
WO2018026890A1 (en) 2016-08-03 2018-02-08 Cymabay Therapeutics Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166853A (en) * 1978-05-05 1979-09-04 The Upjohn Company Antihypertensive 7-trifluoromethyl-4-aminoquinolones
JPH07509694A (ja) * 1992-05-14 1995-10-26 ベイラー・カレッジ・オブ・メディシン 突然変異したステロイドホルモン受容体，その使用方法および遺伝子治療のための分子スイッチ
US5364791A (en) * 1992-05-14 1994-11-15 Elisabetta Vegeto Progesterone receptor having C. terminal hormone binding domain truncations
DE4407139A1 (de) * 1994-03-04 1995-09-07 Thomae Gmbh Dr K Aryl-1-azacycloalkane und deren Salze, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung
CA2214288C (en) * 1996-09-18 2006-07-18 Lonza Ag Process for the preparation of 1-acyl-4-arylpiperidines
EP0837065A1 (de) * 1996-10-16 1998-04-22 Ciba SC Holding AG Phenylglycidylether-HALS
JP4516717B2 (ja) * 2000-07-13 2010-08-04 アボット・ラボラトリーズ ヒスタミン−３受容体リガンドとしての１，３−二置換ピロリジン及び１，３，３−三置換ピロリジン並びにそれらの治療的応用
US6515013B2 (en) * 2000-07-13 2003-02-04 Abbott Laboratories 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications
CA2418369A1 (en) * 2000-08-08 2002-02-14 Richard Apodaca Non-imidazole aryloxyalkylamines as h3 receptor ligands
CA2439152C (en) * 2001-02-28 2008-06-17 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
WO2002076440A2 (en) * 2001-03-23 2002-10-03 Elan Pharmaceuticals, Inc. Methods of treating alzheimer's disease with piperidin derivates
US7459461B2 (en) * 2001-10-19 2008-12-02 Ortho-Mcneil Pharmaceutical, Inc. Phosphonic acid compounds as inhibitors of serine proteases

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113453762A (zh) * 2019-03-05 2021-09-28 卫材R&D管理有限公司 五环杂环化合物
CN113453762B (zh) * 2019-03-05 2024-06-07 卫材R&D管理有限公司 五环杂环化合物

Also Published As

Publication number Publication date
CA2521899A1 (en) 2004-10-21
MXPA05010816A (es) 2005-12-05
WO2004089373A1 (en) 2004-10-21
EP1610786B9 (en) 2008-02-27
BRPI0409110A (pt) 2006-03-28
CO5640135A2 (es) 2006-05-31
EP1610786B1 (en) 2007-06-20
DE602004007119D1 (de) 2007-08-02
NO20055256L (no) 2006-01-10
JP2006522771A (ja) 2006-10-05
ATE365039T1 (de) 2007-07-15
GB0308333D0 (en) 2003-05-14
ES2288681T3 (es) 2008-01-16
DE602004007119T2 (de) 2008-02-21
ZA200507795B (en) 2006-07-26
KR20050111638A (ko) 2005-11-25
RU2005134006A (ru) 2006-04-10
US20060205774A1 (en) 2006-09-14
NO20055256D0 (no) 2005-11-09
AR044006A1 (es) 2005-08-24
TW200503710A (en) 2005-02-01
EP1610786A1 (en) 2006-01-04
MA27726A1 (fr) 2006-01-02
AU2004228949A1 (en) 2004-10-21
AU2004228949B2 (en) 2006-11-02
IS8118A (is) 2005-11-08

Similar Documents

Publication Publication Date Title
CN1118452C (zh) 1－[(1－取代－4－哌啶基)甲基]－4－哌啶衍生物、其生产方法、含有该化合物的药物组合物和这些化合物的中间体
EP1610786B1 (en) 4-(4-(heterocyclylalkoxy phenyl)-1-(heterocyclyl-carbonyl)piperidine derivatives and related compounds as histamine h3 antagonists for the treatment of neurological diseases such as alzheimer's
CN1190432C (zh) 作为5－htib拮抗药的哌嗪衍生物
CN1061977C (zh) 芳基取代的杂环
CN1273451C (zh) 哌啶mch拮抗剂及其治疗肥胖症的用途
CN1072666C (zh) 用作速激肽拮抗剂的(氮杂环丁－1－基烷基)内酰胺
CN1094723A (zh) 羧酰胺衍生物
HK1049118A1 (zh) 金属蛋白酶抑制剂
CN1902171A (zh) 用作ccr－5拮抗剂的苄醚胺化合物
CN1585749A (zh) 类大麻苷受体配体
CN1229373C (zh) 作为神经激肽1拮抗剂的哌啶衍生物
CN1135218A (zh) 哌啶类衍生物
CN1471511A (zh) 用作半光氨酸蛋白酶可逆抑制剂的螺杂环腈
CN1211572A (zh) 趋化细胞因子受体－3拮抗剂
CN1633414A (zh) 化合物
CN1545509A (zh) 用作趋化因子受体活性调节剂的哌啶衍生物
HK1044337A1 (en) Amide compounds
CN1787818A (zh) 趋化因子受体活性的氨基环丁基酰胺调节剂
CN1067889A (zh) 取代的n-(1-烷基-3-羟基-4-哌啶基)苯甲酰胺的制备方法
CN1835944A (zh) 作为ccr－5拮抗剂的喹啉酰胺衍生物
CN1671662A (zh) 哌啶衍生物及其制备方法和用途
CN1361775A (zh) 新的二苯基哌啶衍生物
CN1337948A (zh) 含有炔基的异羟肟酸衍生物、其制备及其作为基质金属蛋白酶抑制剂/TNF－α转变酶抑制剂的用途
CN1599722A (zh) 作为毒蕈碱受体拮抗剂的4－哌啶基烷基胺衍生物
CN1414961A (zh) 作为神经激肽拮抗剂的取代的肟和腙

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication